BRBruna Silveira da Rosa

Bruna Silveira da Rosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruna Silveira da Rosa has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mental health issues in adolescent mothers and young adult mothers: the Brazilian context

    by Amanda Ferreira de Carvalho, Daniela Dal Forno Kinalski Guaranha, Bruna Marmett, Júlia Mathias Reis, Carmem Lisiane Escouto de Souza, Bruna Silveira da Rosa, Tiago Chagas Dalcin, Sérgio Luis Amantea


  • Open Access

    Estudo multicêntrico sobre a saúde mental de mães adolescentes brasileiras, 2024

    by Amanda Ferreira de Carvalho, Daniela Dal Forno Kinalski Guaranha, Bruna Marmett, Júlia Mathias Reis, Bruna Silveira da Rosa, Carmem Lisiane Escouto de Souza, Tiago Chagas Dalcin, Sérgio Luís Amantéa, Frederico Viana Machado

    Resumo Objetivo Analisar a saúde mental das mães adolescentes brasileiras usuárias do Sistema Único de Saúde. Métodos Trata-se de um estudo multicêntrico realizado com 583 mães adolescentes (10-19 anos). As participantes responderam ao questionário sobre variáveis sociodemográficas, saúde mental e apoio familiar. Os resultados foram apresentados como frequências absolutas e relativas. A associação entre desfecho e variáveis foram investigadas por meio de regressão de Poisson. Resultados Houve algum nível de depressão em 61,9% das adolescentes e de ansiedade em 63,8%. Esses sintomas associaram-se à falta de apoio familiar (p-valor<0,001), à perda de amigos da escola (p-valor<0,001), ao diagnóstico de depressão pós-parto (p-valor<0,001) e ao diagnóstico de depressão ou ansiedade antes ou durante a gestação (p-valor<0,001). As adolescentes diagnosticadas com problemas de saúde mental que estavam em acompanhamento totalizaram 15,9%. As principais barreiras identificadas foram dificuldades de acesso ao suporte psicólogo, desinteresse e falta de estímulo. Conclusão O estudo revelou preocupantes taxas de depressão e ansiedade entre as adolescentes. Enfatizou-se a importância do apoio familiar, cuja ausência está ligada ao aumento dos sintomas de sofrimento mental. Destacou-se o impacto negativo da perda de vínculos sociais e do histórico de problemas de saúde mental, como a depressão pós-parto. As adolescentes que estavam em acompanhamento psicológico totalizaram 15,9%, o que evidenciou barreiras de acesso à saúde mental. Os resultados sublinharam a urgência de intervenções e políticas públicas para melhorar o acesso ao suporte psicológico e promover a saúde mental dessa população.


  • Open Access

    A multicenter study on the mental health of Brazilian adolescent mothers, 2024

    by Amanda Ferreira de Carvalho, Daniela Dal Forno Kinalski Guaranha, Bruna Marmett, Júlia Mathias Reis, Bruna Silveira da Rosa, Carmem Lisiane Escouto de Souza, Tiago Chagas Dalcin, Sérgio Luís Amantéa, Frederico Viana Machado

    Objective To analyze the mental health of Brazilian adolescent mothers who use the Unified Health System (Sistema Único de Saúde, SUS). Methods This is a multicenter study conducted with 583 adolescent mothers (10-19 years old). The participants responded to a questionnaire on sociodemographic variables, mental health and family support. The results were presented as absolute and relative frequencies. The association between outcome and variables was investigated using Poisson regression. Results Some level of depression (61.9%) and anxiety (63.8%) was present in the adolescents. These symptoms were associated with a lack of family support (p-value<0.001), the loss of school friends (p-value<0.001), the diagnosis of postpartum depression (p-value<0.001), and the diagnosis of depression or anxiety before or during pregnancy (p-value<0.001). 15.9% of the adolescents diagnosed with mental health conditions were being treated. The main barriers identified were difficulties in access to psychological support, lack of interest and lack of encouragement. Conclusion The study revealed worrying rates of depression and anxiety among teenage girls. The importance of family support was emphasized, the absence of which is linked to increased symptoms of mental distress. The impact of the loss of social ties and a history of mental health problems, such as postpartum depression, is highlighted. 15% of the adolescents had psychological monitoring, which makes evident the barriers to access to mental health. The results underline an urgent need for interventions and public policies to improve access to psychological support and to promote the mental health of this population.


  • Open Access

    Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

    by Beatriz Arns, Andre C. Kalil, Guilherme G. L. Sorio, Emerson Boschi, Ana Carolina Peçanha Antonio, Juliana Peçanha Antonio, Daniella Cunha Birriel, Daniel Haase Lanziotti, Frederico da Cunha Abbott, Glecia Carla Rocha, et al.

    Shorter courses of antimicrobial therapy have been shown to be non-inferior to longer durations for the management of several infections. However, data on critically ill patients with severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB) are scarce. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we assessed the non-inferiority of 7-day versus 14-day antimicrobial therapy for patients with intensive care unit (ICU)-acquired severe infections by MDR-GNB. This was a randomised multicenter, open-label, parallel controlled, non-inferiority trial. Adult patients with severe infections by MDR-GNB initiated ≥ 48 h of ICU admission were eligible if they were hemodynamically stable and without fever > 48 h on the 7th day of appropriate antimicrobial therapy. Patients were 1:1 randomised to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14 (± 1) days. The primary outcome was clinical failure, defined as death or relapse of infection within 28 days of randomisation. An upper edge of the two-tailed 95% confidence interval (CI) of the delta between the clinical failure rate in the 7- and the 14-day lower than 10% in both intention-to-treat (ITT) and per protocol (PP) analyses was set as the non-inferiority criteria. A total of 106 patients composed the ITT population: 59 and 47 allocated to 7- and 14-day groups, respectively. The PP population included 75 patients: 47 and 28 in the 7- and 14-day groups, respectively. Clinical failure occurred in 42.4% and 44.7% of the ITT population in 7- and 14-day groups, respectively, (risk difference (RD) − 2.3, 95%CI − 21.3 to 16.7), and in 46.8% and 50.0% of the PP population in 7- and 14-day groups, respectively (RD − 3.2, 95%CI − 26.6 to 20.2). Most infections were of the respiratory tract (73/68.9%) and caused by carbapenem-resistant Enterobacterales (42/39.6%). The study was interrupted before reaching planned sample size due to low recruitment rate. The OPTIMISE trial could not determine the non-inferiority of 7-day compared to 14-day therapy for severe infections caused by MDR-GNB due to early termination related to the low recruitment rate. Trial registration: NCT05210387 on January 13, 2022.


  • Open Access

    A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol

    by Beatriz Arns, Jaqueline Driemeyer C. Horvath, Gabriela Soares Rech, Guilhermo Prates Sesin, Crepin Aziz Jose Oluwafoumi Agani, Bruna Silveira da Rosa, Tiago Marcon dos Santos, Liliane Spencer Bittencourt Brochier, Alexandre Biasi Cavalcanti, Bruno Martins Tomazini, et al.

    Introduction Shorter courses of antimicrobials have been shown to be non-inferior to longer, “traditional” duration of therapies, including for some severe healthcare-associated infections, with a few exceptions. However, evidence is lacking regarding shorter regimes against severe infections by multidrug-resistant Gram-negative bacteria (MDR-GNB), which are often caused by distinct strains and commonly treated with second-line antimicrobials. In the duratiOn of theraPy in severe infecTIons by MultIdrug-reSistant gram-nEgative bacteria (OPTIMISE) trial, we aim to assess the non-inferiority of 7-day versus 14-day antimicrobial therapy in critically ill patients with severe infections caused by MDR-GNB. Methods This is a randomized, multicenter, open-label, parallel controlled trial to assess the non-inferiority of 7-day versus 14-day of adequate antimicrobial therapy for intensive care unit (ICU)-acquired severe infections by MDR-GNB. Adult patients with severe infections by MDR-GNB initiated after 48 h of ICU admission are screened for eligibility. Patients are eligible if they proved to be hemodynamically stable and without fever for at least 48 h on the 7th day of adequate antimicrobial therapy. After consenting, patients are 1:1 randomized to discontinue antimicrobial therapy on the 7th (± 1) day or to continue for a total of 14th (± 1) days. Planned Outcomes The primary outcome is treatment failure, defined as death or relapse of infection within 28 days after randomization. Non-inferiority will be achieved if the upper edge of the two-tailed 95% confidence interval of the difference between the clinical failure rate in the 7-day and the 14-day group is not higher than 10%. Conclusion The OPTIMISE trial is the first randomized controlled trial specifically designed to assess the duration of antimicrobial therapy in patients with severe infections by MDR-GNB. Trial Registration ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE).